EVENTS | VIEW CALENDAR
Activiomics signs research agreement with Kyowa Hakko Kirin
LONDONóCancer research firm Activiomics last month signed a research agreement with Japanese pharmaceutical company Kyowa Hakko Kirin under which Activiomics will apply its TIQUAS phosphoproteomics platform to elucidate signaling mechanisms of lead compounds in relevant cell-based systems.
The agreement was signed as part of Activiomics' recently announced strategic partnership with BioFocus.
Activiomics uses its mass spectrometry-based methods to analyze and interpret cell signaling pathway activity, generating high-value information for the pharmaceutical and biotechnology industry, according to a press release issued by the company.
"We've engaged with Activiomics because we recognize that Activiomics' label-free phosphoproteomics approach can provide unique insights into signaling pathway activity, information that can complement and extend our existing gene expression datasets. This technology will enable us to better understand cell signaling mechanisms of our lead compounds and could enable us to identify important biomarkers," said Dr. Etsuo Ohshima, managing officer of Kyowa Hakko Kirin, in a statement.
Financial terms of the partnership were not disclosed.